Related Experiment Video

Updated: Jun 18, 2026

Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury
08:27

Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury

Published on: May 21, 2018

Aerosolized vancomycin for the treatment of MRSA after lung transplantation

Don Hayes1, Brian S Murphy, Timothy W Mullett

  • 1Department of Pediatrics, College of Medicine, University of Kentucky, Lexington, Kentucky 40536,, USA. don.hayes@uky.edu

Respirology (Carlton, Vic.)
|November 10, 2009
PubMed

Insights

Lung transplantation offers life extension for cystic fibrosis patients. Aerosolized vancomycin successfully treated a lung transplant recipient for methicillin-resistant Staphylococcus aureus infection, a novel approach.

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Transplantation Medicine

Background:

  • Lung transplantation is a critical treatment for end-stage cystic fibrosis lung disease.
  • Pre-existing airway pathogens, particularly methicillin-resistant Staphylococcus aureus (MRSA), pose significant post-transplant infection risks.
  • Aerosolized vancomycin is established for MRSA treatment in cystic fibrosis but its use in lung transplant recipients is unreported.

Observation:

  • A lung transplant recipient presented with a methicillin-resistant Staphylococcus aureus (MRSA) infection.
  • This case explored the efficacy of aerosolized vancomycin in managing post-lung transplantation MRSA infection.

Findings:

  • Successful treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection was achieved using aerosolized vancomycin in a lung transplant recipient.
  • This represents the first reported instance of aerosolized vancomycin use for MRSA infection in this patient population.

Implications:

  • Aerosolized vancomycin may be a viable therapeutic option for managing MRSA infections in lung transplant recipients.
  • This case highlights a potential strategy to mitigate post-transplant infectious complications in cystic fibrosis patients.
  • Further research is warranted to establish the safety and efficacy of this treatment modality.

More Related Videos

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases03:22

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Published on: March 1, 2024

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...